Vol 10, No 1 (2024)
Case report
Published online: 2024-01-24

open access

Page views 182
Article views/downloads 55
Get Citation

Connect on Social Media

Connect on Social Media

Use of mycophenolate mofetil in refractory relapsing polychondritis

Przemyslaw Borowy12, Jakub Smyk1, Patrycja Major1, Natalia Mglej1, Bogdan Batko12
Rheumatology Forum 2024;10(1):43-47.

Abstract

Relapsing polychondritis (RP) remains a difficult-to-treat disease of unknown aetiology and uncertain prognosis. Based on McAdam's criteria, rheumatoid arthritis (RA) was diagnosed in a 51-year-old female patient, and sequential therapy with dapsone — followed by naproxen and methylprednisolone — was initiated without achieving full remission. During the following years, the patient developed new locations of polychondritis (nose, epiphyses of long bones) and episcleritis. Methotrexate (MTX) was started, which was changed to mycophenolate mofetil (MM) due to adverse effects, resulting in sustained clinical improvement. There were no relapses during the subsequent 12 months of follow-up. The use of MM with good therapeutic effect in our patient is one of the few reported cases of such therapy in a patient with RP.

Article available in PDF format

View PDF Download PDF file

References

  1. Hong G, Kim H. Clinical characteristics and treatment outcomes of patients with relapsing polychondritis with airway involvement. Clin Rheumatol. 2013; 32(9): 1329–1335.
  2. Arnaud L, Mathian A, Haroche J, et al. Pathogenesis of relapsing polychondritis: a 2013 update. Autoimmun Rev. 2014; 13(2): 90–95.
  3. Goldenberg G, Sangueza OP, Jorizzo JL. Successful treatment of relapsing polychondritis with mycophenolate mofetil. J Dermatolog Treat. 2006; 17(3): 158–159.
  4. McAdam LP, O'Hanlan MA, Bluestone R, et al. Relapsing polychondritis: prospective study of 23 patients and a review of the literature. Medicine (Baltimore). 1976; 55(3): 193–215.
  5. Sosada B, Loza K, Bialo-Wojcicka E. Relapsing polychondritis. Case Rep Dermatol Med. 2014; 2014: 791951.
  6. Rednic S, Damian L, Talarico R, et al. Relapsing polychondritis: state of the art on clinical practice guidelines. RMD Open. 2018; 4(Suppl 1): e000788.
  7. Pietrzak Z, Putała-Pośpiech M, Józefowicz-Korczyńska M, et al. Relapsing polychondritis — diagnostic problem. Dermatol Rev. 2015; 6: 528–534.
  8. Petitdemange A, Sztejkowski C, Damian L, et al. Treatment of relapsing polychondritis: a systematic review. Clin Exp Rheumatol. 2022; 40 Suppl 134(5): 81–85.
  9. Borgia F, Giuffrida R, Guarneri F, et al. Relapsing Polychondritis: An Updated Review. Biomedicines. 2018; 6(3).
  10. Arnaud L, Costedoat-Chalumeau N, Mathian A, et al. Collaborators. French practical guidelines for the diagnosis and management of relapsing polychondritis. Rev Med Interne. 2023; 44(6): 282–294.
  11. Vitale A, Sota J, Rigante D, et al. Relapsing Polychondritis: an Update on Pathogenesis, Clinical Features, Diagnostic Tools, and Therapeutic Perspectives. Curr Rheumatol Rep. 2016; 18(1): 3.
  12. Mathian A, Miyara M, Cohen-Aubart F, et al. Relapsing polychondritis: A 2016 update on clinical features, diagnostic tools, treatment and biological drug use. Best Pract Res Clin Rheumatol. 2016; 30(2): 316–333.
  13. Wallace ZS, Stone JH. Refractory relapsing polychondritis treated with serial success with interleukin 6 receptor blockade. J Rheumatol. 2013; 40(1): 100–101.